RecruitingNCT02269592

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome

Sponsor

Dana-Farber Cancer Institute

Enrollment

10,000 participants

Start Date

Aug 1, 2014

Study Type

OBSERVATIONAL

Conditions

Smoldering Multiple Myeloma Myelodysplastic Syndromes Waldenstrom Macroglobulinemia Hematological Malignancies Monoclonal Gammopathy of Undetermined Significance (MGUS)B-cell Malignancy, Low-grade Myelodysplastic Syndrome With Low-grade Lesions IgG Monoclonal Gammopathy of Uncertain Significance

Summary

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered. Some of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called "molecular" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study. This research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying early-stage or pre-cancerous blood conditions — such as MGUS, smoldering myeloma, early MDS, and early CLL — to understand what causes some people to progress to full cancer while others do not. **You may be eligible if...** - You have been diagnosed with or are suspected to have an early or precursor blood condition, including: early MDS (a bone marrow disorder), MGUS or smoldering multiple myeloma (abnormal protein in the blood), or monoclonal B-cell lymphocytosis (CLL precursor) - You are able to provide blood or tissue samples for research **You may NOT be eligible if...** - You have already been diagnosed with active, full-stage blood cancer - You are not willing to provide samples or consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.